<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118517</article-id><article-id pub-id-type="publisher-id">ACM-44645</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_35020776.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  复发转移性结直肠癌的早期诊断及治疗
  Early Diagnosis and Treatment of Recurrent and Metastatic Colorectal Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>继凡</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>罗</surname><given-names>诗樵</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杜</surname><given-names>波</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>重庆医科大学附属第一医院，肝胆外科，重庆</addr-line></aff><aff id="aff2"><addr-line>重庆市开州区人民医院肝胆乳甲外科，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3542</fpage><lpage>3546</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  随着生活方式和饮食结构的改变，结直肠癌的发病率和死亡率呈现逐年升高的趋势，已成为在世界上威胁人类健康的最常见的恶性肿瘤之一。随着人们健康意识的提高，结直肠癌及早被发现。其治疗的方式主要为手术切除治疗，但是5年生存率仍较低，一般结直肠癌根治术后复发率达1/3左右，占治疗失败病人的80%以上。其死亡的主要原因是远处转移和复发。包括肿瘤切除区域局部复发、临近脏器、引流区域淋巴结、腹壁切口、肝脏、骨骼、肺等的转移癌。上述复发类型可并存，形成腹腔内广泛区域性复发。结直肠癌复发转移后若不治疗的5年生存率不足5%；而再次手术根治后5年生存率可达30%~50%，可以和首次手术的效果相媲美。所以早期诊断和及时治疗复发转移性结直肠癌仍是医学上值得探讨的话题。
   With the changes in lifestyle and diet, the incidence and mortality of colorectal cancer are increasing year by year, and it has become one of the most common malignant tumors that threaten human health in the world. With the improvement of people’s health awareness, colorectal cancer is found early. The main method of treatment is surgical resection, but the 5-year survival rate is still low. Generally, the recurrence rate after radical resection of colorectal cancer is about 1/3, accounting for more than 80% of patients with treatment failure. The main cause of his death was distant metastasis and recurrence, including local recurrence in the area where the tumor was removed, metastatic cancers in adjacent organs, drainage area lymph nodes, abdominal wall incisions, liver, bones, lungs, etc. The above recurrence types can coexist, forming extensive regional recurrence in the abdominal cavity. After colorectal cancer recurrence and metastasis, the 5-year survival rate without treatment is less than 5%; and the 5-year survival rate after reoperation can reach 30%~50%, which can be comparable to the effect of the first operation. Therefore, early diagnosis and timely treatment of recurrent and metastatic colorectal cancer are still topics worth discussing in medicine.
 
</p></abstract><kwd-group><kwd>复发转移性，结直肠癌，早期诊断及治疗, Recurrent and Metastatic</kwd><kwd> Colorectal Cancer</kwd><kwd> Early Diagnosis and Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>随着生活方式和饮食结构的改变，结直肠癌的发病率和死亡率呈现逐年升高的趋势，已成为在世界上威胁人类健康的最常见的恶性肿瘤之一。随着人们健康意识的提高，结直肠癌及早被发现。其治疗的方式主要为手术切除治疗，但是5年生存率仍较低，一般结直肠癌根治术后复发率达1/3左右，占治疗失败病人的80%以上。其死亡的主要原因是远处转移和复发。包括肿瘤切除区域局部复发、临近脏器、引流区域淋巴结、腹壁切口、肝脏、骨骼、肺等的转移癌。上述复发类型可并存，形成腹腔内广泛区域性复发。结直肠癌复发转移后若不治疗的5年生存率不足5%；而再次手术根治后5年生存率可达30%~50%，可以和首次手术的效果相媲美。所以早期诊断和及时治疗复发转移性结直肠癌仍是医学上值得探讨的话题。</p></sec><sec id="s2"><title>关键词</title><p>复发转移性，结直肠癌，早期诊断及治疗</p></sec><sec id="s3"><title>Early Diagnosis and Treatment of Recurrent and Metastatic Colorectal Cancer<sup> </sup></title><p>Jifan Xu<sup>1</sup>, Peng Zhang<sup>1</sup>, Shiqiao Luo<sup>2</sup>, Bo Du<sup>1*</sup></p><p><sup>1</sup>People’s Hospital of Kaizhou District Hepatobiliary Surgery, Chongqing</p><p><sup>2</sup>First Affiliated Hospital of Chongqing Medical University, Chongqing</p><p><img src="//html.hanspub.org/file/34-1572382x5_hanspub.png?20210819171858807" /></p><p>Received: Jul. 13<sup>th</sup>, 2021; accepted: Aug. 12<sup>th</sup>, 2021; published: Aug. 19<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/34-1572382x6_hanspub.png?20210819171858807" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>With the changes in lifestyle and diet, the incidence and mortality of colorectal cancer are increasing year by year, and it has become one of the most common malignant tumors that threaten human health in the world. With the improvement of people’s health awareness, colorectal cancer is found early. The main method of treatment is surgical resection, but the 5-year survival rate is still low. Generally, the recurrence rate after radical resection of colorectal cancer is about 1/3, accounting for more than 80% of patients with treatment failure. The main cause of his death was distant metastasis and recurrence, including local recurrence in the area where the tumor was removed, metastatic cancers in adjacent organs, drainage area lymph nodes, abdominal wall incisions, liver, bones, lungs, etc. The above recurrence types can coexist, forming extensive regional recurrence in the abdominal cavity. After colorectal cancer recurrence and metastasis, the 5-year survival rate without treatment is less than 5%; and the 5-year survival rate after reoperation can reach 30%~50%, which can be comparable to the effect of the first operation. Therefore, early diagnosis and timely treatment of recurrent and metastatic colorectal cancer are still topics worth discussing in medicine.</p><p>Keywords:Recurrent and Metastatic, Colorectal Cancer, Early Diagnosis and Treatment</p><disp-formula id="hanspub.44645-formula22"><graphic xlink:href="//html.hanspub.org/file/34-1572382x7_hanspub.png?20210819171858807"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/34-1572382x8_hanspub.png?20210819171858807" /> <img src="//html.hanspub.org/file/34-1572382x9_hanspub.png?20210819171858807" /></p></sec><sec id="s5"><title>1. 复发结直肠癌的早期诊断</title><p>结直肠癌术后复发的早期发现对病人预后至关重要。复发癌早期发现的关键在于病人的定期随诊复查。症状上如出现便血、黏液血便、局部肿块、便秘、腹痛、会阴部坠胀、肛门指检扪及肿块等均提示复发可能。早期患者的非特异性症状常多不明显，不引起重视，一旦症状出现时则病变已晚甚至有远处转移的可能。实验室检查如再次的大便隐血阳性、术后CEA降至正常后再次升高均提示复发转移的可能。此时需要进一步完善肠镜、CT等检查明确疾病的状态。</p><p>结直肠癌复发大多发生于首次手术后的6个月~2年内，高峰为6~12个月，被称为“结直肠癌复发高危险时间”。5年以上发生者仅占5% [<xref ref-type="bibr" rid="hanspub.44645-ref1">1</xref>]。因而，对结直肠癌术后病人定期复查尤其重要。通过症状、常规体检发现的复发，常常失去手术时机。所以根据指南 [<xref ref-type="bibr" rid="hanspub.44645-ref2">2</xref>] 一般建议3年内随访者每3个月复查一次，5年内每半年门诊随访。特别是对那些高危复发人群如Duke’s B期C期，肿瘤分化差者及CEA持续升高者更应该积极密切复查和随访。定期监测CEA及结肠镜检查、CT等对降低总死亡率有显著影响，复发结直肠癌的早期诊断、早期发现复发病灶如同原发癌一样也可以大大提高切除率，提高其肿瘤切除率，从而提高生存率。</p></sec><sec id="s6"><title>2. 预防肿瘤复发及转移的措施</title><p>结直肠癌术后复发和许多因素有关，患者本身癌家族史、免疫功能低下；首次手术仅满足于将肿瘤切除清扫范围不彻底、肠系膜切除不足致癌细胞系膜内及引流淋巴结残留、淋巴结微转移等，没有严格遵守无瘤术原则，盲目采用小切口进行钝性分离致手术中外力挤压导致肿瘤细胞脱落进入血循环，引起播散和转移；肿瘤分化程度差，存在组织浸润，存在多中心病灶及亚临床病灶；术后未采针对肿瘤的积极有效的综合治疗；肠镜检查、术前肠梗阻、肠穿孔、逆行灌肠等癌细胞脱落腹腔播散转移等等，种种因素都增加患者复发转移的机会 [<xref ref-type="bibr" rid="hanspub.44645-ref3">3</xref>]。这就要求我们对于术后病理分化较差，应在术后加强辅助化疗及放疗，定期复查，尽早发现诊断转移复发。术前、术中严格的遵循无瘤原则，采取规范的手术方式。结肠癌按不同病变部位力求做到按照原则完整的行左半、右半结肠切除。全直肠系膜切除术(TME)已经成为直肠癌根治术的金标准，能显著降低直肠癌术后复发。直肠严格按照TME原则进行，局部切除范围要足、肠外淋巴结需要彻底清扫及所属肠系膜，在手术中避免用力挤压肿瘤。术前行新辅助放化疗，也是减少结直肠癌复发的重要方法。</p></sec><sec id="s7"><title>3. 复发转移性结直肠癌的再次手术治疗</title><p>直肠术后患者多营养状态较差，心理压力较大，复发后其局部解剖结构发生了显著变化，再手术时腹腔广泛粘连使手术难度陡增。但是随着手术方式的逐渐改进，先进手术器械的发展及多学科的合作，为结直肠癌术后复发的治疗提供了更好的条件。近年来，复发性结直肠癌的根治性再手术和提高术后生存率已经越来越引起外科医师的注意。一般认为符合下列条件者应争取手术治疗：患者一般情况可，心肺功能能耐受手术；肿瘤能够的完整的切除，包括远处转移的肝、肺等转移病灶；通过姑息性减瘤手术或造瘘术解除梗阻，改善了生存质量，延长患者生存时间，使得部分患者受益。对于腹腔内广泛转移，有血性腹水或是恶性腹水者，有骨转移、肺转移等则不适合进行再次手术治疗 [<xref ref-type="bibr" rid="hanspub.44645-ref4">4</xref>]。</p><p>术式的选择要根据复发的部位、病理类型、周围浸润程度、淋巴结是否转移，应首先考虑到根治性术式，其次才是功能。吻合口局部复发者应该争取再次切除，尤其是首次手术不彻底者；对于盆腔内复发，应该施行复合切除，即完整切除病灶、受累盆壁脏器；对于腹壁、盆腔广泛转移复发而无法行根治性切除者，则切除主要种植转移灶，降低瘤负荷；对于合并肠梗阻且肿瘤无法切除者，则行姑息性肠造口或是肠肠短路手术以解除梗阻。总的治疗原则是能够手术治疗的应积极手术，能行根治性手术的应力争根治。但不是所有的患者能从中受益，再次手术的时机以及手术方式的选择等均需要慎重。处理的好可以明显延长患者的生存时间，减轻患者的疼痛；否则不仅增加患者的痛苦和经济压力，而且有时会加速肿瘤的生长，缩短病人的生存时间。术前准确应该判断是否手术切除复发病灶、实施何种手术、联合切除哪些脏器对患者最好 [<xref ref-type="bibr" rid="hanspub.44645-ref5">5</xref>]。对复发转移结直肠癌行再次手术的难度和风险应有清醒认识，所以术前应该积极的评估疾病的状态，评估肿瘤是否复发的类型和部位，复发肿瘤与周围脏器的关系等；术中仔细的分离避免副损伤，当然应该结合术者的经验及全身状况做出综合的判断决定是否行再次手术。</p><p>再次手术的目的一是通过再次手术达到根治的目的；其二是缓解肿瘤复发引起的症状，减轻患者的痛苦，提高生存质量。对于合并远处转移患者而又符合手术指征的患者的治疗仍存在着争议，如合并肝脏、肺部的转移，同期切除还是分期切除一直是争论的焦点。国内学者多数认为同期切除不仅较少了费用，且规避了疾病进展的风险，所以主张行同期切除。而国外规范认为同期切除手术并发症多，多数主张分期切除。其实应该根据患者基本情况、病灶的可切除性决定治疗方式 [<xref ref-type="bibr" rid="hanspub.44645-ref6">6</xref>]。</p><p>转移灶切除术后最常见的是再次复发，其处理也是较为棘手的。对于再次转移复发的患者按照初发复发转移进行处理似乎是合适的, 在考虑了手术风险和生存几率的基础之上可以行再切除。尤其是肝脏的单发或3个病灶以下者、复发时间间隔时间长的转移灶患者可以进行多次的切除或是射频消融。对于其他部位再次复发是否应该切除还是值得探讨。复发转移灶再次手术切除较上一次手术难度明显增大，术后并发症发生率和死亡率均有所增加，故应严格掌握适应证 [<xref ref-type="bibr" rid="hanspub.44645-ref7">7</xref>]。</p></sec><sec id="s8"><title>4. 化疗及靶向药物治疗</title><p>近年来由于化疗药物疗效的提高及靶向药物的出现，新辅助化疗能缩小肿瘤病灶，减小肿瘤的浸润，降低肿瘤分期，使不能切除的肿瘤变为可切除，提高治愈性手术切除率，减少复发率。再次手术可避免不必要的过多的化疗造成的毒副反应。对于先前未行放射治疗的术后复发者，放射治疗不失为一种被大多数病人接受的姑息性治疗方法，可明显减轻症状，可延长生存期。当然对于再次术后复发可以选择放疗、化疗等手段延缓疾病的进展。所以所有的治疗手段是相辅相成、互相补充的。我们如能将新辅助化疗、手术和术后辅助综合治疗有机地结合起来能大大地降低术后复发率和提高生存率，以期最大程度上使患者受益。最好是在化、放疗保护及综合治疗情况下的再手术，不要盲目再手术 [<xref ref-type="bibr" rid="hanspub.44645-ref8">8</xref>]。</p><p>奥沙利铂、伊立替康和氟尿嘧啶是转移性结直肠癌化疗的3类基本药物，和其他药物组成的FOLFOX、FOLFIRI应用至今，也被证实效果最好。分子靶向药物的出现为复发转移性结直肠癌的治疗带来了一丝曙光。分子靶向药物是在细胞分子水平肿瘤调控的信号转导通路，使肿瘤细胞特异性死亡的药物。其不良反应更小，对化疗药物耐药的病例仍有效 [<xref ref-type="bibr" rid="hanspub.44645-ref9">9</xref>]。联合传统化疗药物可有效改善患者预后，提高了晚期转移性结直肠癌的生存期，安全性好，毒副反应可耐受，用药方便，均可作为晚期复发转移性结直肠癌化疗的有效选择，合理的用药剂量以及及时对症处理可有效减轻毒副作用。但是对于分子靶向药物如何与化疗方案联合仍然是值得探讨的问题。</p><p>作用于血管内皮生长因子(VEGF)的分子靶向药物如贝伐单抗、作用于表皮生长因子受体(EGFR)的分子靶向药物如西妥昔单抗，对晚期结直肠癌的治疗作用得到各国专家的共识。其他的如EGFR的小分子酪氨酸激酶抑制剂，其它分子靶向药物如抑制环氧化酶(COX-2)，EGFR酪氨酸激酶抑制剂等靶向药物也为分子靶向治疗发展带来更广阔的前景。自杀基因治疗、癌基因及抑癌基因治疗、免疫基因治疗、抗血管生长的基因治疗等均停留在概念及理论研究水平。其他多种分子靶向药物治疗肠癌的临床研究正在进行中，期待有更多的靶向药物应用于结直肠癌治疗中。由于分子靶向药物价格昂贵，目前仅使用于晚期转移性结直肠癌一线治疗或化疗二线治疗药物，并不适合常规治疗 [<xref ref-type="bibr" rid="hanspub.44645-ref10">10</xref>]。<sup> </sup></p><p>通过多学科团队(MDT)协作分析 [<xref ref-type="bibr" rid="hanspub.44645-ref11">11</xref>]，在大量临床研究和转化研究的基础上，根据病人状况和治疗目标设定治疗策略是目前结直肠癌重要的治疗原则。合理应用分子靶向药物，优化最佳治疗方案，并选择恰当的时机，是实现治疗目标、改变病人疾病转归的重要保证。肿瘤学正在快速发展，要求医生根据肿瘤的基因型和生物学特性个体化治疗，从而达到精准化疗的目的，化疗药物的选用，应根据患者的个体素质和肿瘤生物学行为而定。对于复发转移性结直肠癌目前尚无统一的治疗规范，如何将各种治疗手段有机结合起来还需具体情况决定。设计个体化方案，避免过度治疗，采用综合治疗方法有利于提高治疗效果。</p></sec><sec id="s9"><title>文章引用</title><p>许继凡,张 鹏,罗诗樵,杜 波. 复发转移性结直肠癌的早期诊断及治疗Early Diagnosis and Treatment of Recurrent and Metastatic Colorectal Cancer[J]. 临床医学进展, 2021, 11(08): 3542-3546. https://doi.org/10.12677/ACM.2021.118517</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44645-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Tjandra, J.J. and Chan, M.K. (2007) Follow-Up after Curative Resection of Colorectal Cancer: A Meta-Analysis. Diseases of the Colon &amp; Rectum, 50, 1783-1799. &lt;br&gt;https://doi.org/10.1007/s10350-007-9030-5</mixed-citation></ref><ref id="hanspub.44645-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Van Cutsem, E., Nordlinger, B., Cervantes, A. and ESMO Guidelines Working Group (2010) Advanced Colorectal Cancer: ESMO Clinical Practice Guidelines for Treatment. Annals of Oncology, 21, 93-97.  
&lt;br&gt;https://doi.org/10.1093/annonc/mdq222</mixed-citation></ref><ref id="hanspub.44645-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Courtney, D., McDermott, F., Heeney, A. and Winter, D.C. (2014) Clinical Review: Surgical Management of Locally Advanced and Recurrent Colorectal Cancer. Langenbeck’s Archives of Surgery, 399, 33-40.  
&lt;br&gt;https://doi.org/10.1007/s00423-013-1134-x</mixed-citation></ref><ref id="hanspub.44645-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kanemitsu, Y., Shida, D., et al. (2014) Treatment for Locally Recurrent Rectal Cancer. Nippon Shokakibyo Gakkai Zasshi, 111, 2113-2120.</mixed-citation></ref><ref id="hanspub.44645-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Mohan, H.M., Evans, M.D., et al. (2013) Multivisceral Resection in Colorectal Cancer: A Systematic Review. Annals of Surgical Oncology, 20, 2929-2936. &lt;br&gt;https://doi.org/10.1245/s10434-013-2967-9</mixed-citation></ref><ref id="hanspub.44645-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Nakanishi, M., Kuriu, Y., Murayama, Y., et al. (2014) Efficacy of Perioperative Chemotherapy in Patients with Colorectal Cancer Undergoing Hepatectomy for Resectable Synchronous Liver Metastasis. Hepatogastroenterology, 61, 1582-1587.</mixed-citation></ref><ref id="hanspub.44645-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">潘燚, 牛飞玉, 等. 2013年临床肿瘤学重大进展——美国临床肿瘤学会年度报告[J]. 循证医学, 2013, 13(1): 4-29.</mixed-citation></ref><ref id="hanspub.44645-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Ciombor, K.K. and Bekaii-Saab, T. (2013) Emerging Treatments in Recurrent and Metastatic Colorectal Cancer. Journal of the National Comprehensive Cancer Network, 11, S18-S27. &lt;br&gt;https://doi.org/10.6004/jnccn.2013.0217</mixed-citation></ref><ref id="hanspub.44645-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">周爱萍, 王金万. 2013年ASCO会议关于转移性结直肠癌靶向治的热点问题[J]. 中国新药杂志, 2013, 22(17): 2033-2037.</mixed-citation></ref><ref id="hanspub.44645-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Keating, G.M. (2014) Bevacizumab: A Review of Its Use in Advanced Cancer. Drugs, 74, 1891-1925.  
&lt;br&gt;https://doi.org/10.1007/s40265-014-0302-9</mixed-citation></ref><ref id="hanspub.44645-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">姚宏伟, 刘荫华. 直肠癌治疗理念更新——强调术前多学科评估[J]. 中国实用外科杂志, 2009, 29(9): 717-721.</mixed-citation></ref></ref-list></back></article>